PASCAL Precision Transcatheter Valve Repair System
Edwards Lifesciences, LLC · Decision date Oct 20, 2026
What did the FDA approve?
FDA records P220003/S029 as a supplement to PMA P220003, with the supplement type “Panel Track”. The recorded decision is approval, dated Oct 20, 2026.
FDA approval order statement
Approval for the Edwards PASCAL Precision Transcatheter Valve Repair System for expanding the indications to include patients with tricuspid regurgitation. This device is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tricuspid valve repair by a multidisciplinary heart team.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 20, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P220003/S029
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPS
- Decision code
- APPR
- Decision date
- Oct 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Tricuspid valve repair device, percutaneously delivered.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPS
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220003 · Original PMA
PASCAL Precision Transcatheter Valve Repair System
P220003/S029 received
Application receipt date recorded by FDA.
P220003/S033 · Related supplement
PASCAL Precision Transcatheter Valve Repair System
P220003/S028 · Related supplement
PASCAL Ace with Capture Clarity Valve Repair System MR Implant System
P220003/S029 · FDA decision
Panel Track
P220003/S032 · Related supplement
PASCAL Precision Transcatheter Valve Repair System
Timeline entries are records held by MedtechLedger for P220003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Sep 14, 2022 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 9, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 23, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P220003/S029
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records